Montgomery-Asberg Depression Rating Scale (MADRS)

Abstract

The Montgomery-Asberg Depression Rating Scale (MADRS) is a widely utilized rating scale developed specifically to measure the severity of depressive symptoms and, crucially, to track changes in symptomology over time, making it highly sensitive to the effects of therapeutic intervention, such as antidepressant treatment. Comprising ten items, the MADRS is typically administered as a structured or semi-structured interview, with each item scored on a scale from 0 to 6, yielding a total score ranging from 0 to 60. The scale assesses both psychological and somatic aspects of depression, including sadness, tension, sleep disturbance, and suicidal ideation.

Keywords

MADRS, depression, affective disorders, psychopathology, psychometric scale, clinical trials, symptom severity, mood disorders, antidepressant response

Authors

Stuart A. Montgomery, Marie Åsberg

Purpose

The primary purpose of the MADRS is to provide a standardized, objective measure of the severity of depressive illness. Unlike earlier scales, such as the Hamilton Depression Rating Scale (HDRS), the MADRS was specifically designed by Montgomery and Åsberg in 1979 to be highly sensitive to clinical improvement or deterioration, making it an invaluable tool in psychopharmacological research and clinical trials evaluating the efficacy of new treatments. The scale focuses on core symptoms that are expected to change rapidly in response to therapy.

The instrument is used to establish baseline severity before treatment initiation, to monitor therapeutic response throughout the course of care, and to determine remission status. The total score allows clinicians and researchers to categorize the patient’s current state into clear severity levels: normal, mild, moderate, or severe depression.

Construct

The MADRS measures the psychological construct of major depressive episode severity. It captures the essential features of depression across ten domains, encompassing both core emotional and vegetative symptoms. These domains include observable distress (Apparent Sadness), subjective emotional state (Reported Sadness, Inability to Feel), cognitive disturbances (Concentration Difficulties, Pessimistic Thoughts, Suicidal Thoughts), and somatic/vegetative symptoms (Reduced Sleep, Reduced Appetite, Lassitude). The comprehensive nature of these items ensures that the global severity of the depressive state is accurately captured through clinical observation and patient self-report.

Validity

The MADRS demonstrates strong construct validity, consistently correlating highly with other established depression measures while showing unique sensitivity to change. Early studies confirmed that the ten items effectively measure the intended depressive construct. In terms of structural validity, studies—such as the one by Galinowski and Lehert (1995)—have investigated the underlying factor structure of the MADRS, often confirming that the scale is largely unidimensional or, in some cases, composed of two highly correlated factors (a core mood/psychological factor and a somatic factor), especially when utilized during antidepressant treatment.

The instrument’s clinical utility and concurrent validity are supported by its widespread adoption as a primary outcome measure in regulatory submissions for psychiatric medications globally.

Reliability

The MADRS exhibits excellent inter-rater reliability, a critical feature for scales administered via interview. The anchor points provided for each severity level (0, 2, 4, 6) minimize subjective interpretation by the interviewer. The development of standardized administration procedures, such as the Structured Interview Guide for the Montgomery-Asberg Depression Rating Scale (SIGMA) developed by Williams and Kobak (2008), has further enhanced the reliability and standardization of scoring, ensuring consistency across different clinical settings and research sites. This robust psychometrics profile confirms its reliability in assessing change in depressive symptomology.

Factor Analysis

While designed as a single measure of depression severity, the factor analysis of the MADRS has been extensively studied. Most analyses suggest that the scale possesses a strong general factor representing overall depression severity. However, specific studies, particularly those focusing on the scale’s response to treatment, sometimes extract two or three factors. A common two-factor solution separates items related to core mood and cognitive symptoms (e.g., sadness, pessimistic thoughts) from those related to somatic or vegetative symptoms (e.g., reduced sleep, reduced appetite, lassitude). This structural understanding is vital for interpreting differential treatment effects, as certain medications may target somatic symptoms more effectively than others.

Instrument

Test Type: Observer-Rated Rating Scale / Semi-Structured Interview

Format: 10 items, scored 0 to 6 (total score 0–60).

Language Available: Numerous translations are available globally due to its use in international clinical trials.

Population Group: Clinical and General Population

Age Group: Adolescents and Adults

Population Details: Primarily used in patients diagnosed with Major Depressive Disorder (MDD) or other affective disorders.

Test Methodology: The scale is administered by a trained clinician (psychiatrist, psychologist, or nurse) who rates the severity of symptoms experienced by the patient over the preceding three to seven days. Scoring is based on detailed anchor points (0, 2, 4, 6), with intermediate scores (1, 3, 5) used when the symptom falls between anchor descriptors. The total score determines the severity classification:

• 0 to 6 – Normal/Symptom Absent
• 7 to 19 – Mild Depression
• 20 to 34 – Moderate Depression
• >34 – Severe Depression

Keywords

Clinical assessment, psychopharmacology, Montgomery, Åsberg, severity index, psychometrics, clinical interview, SIGMA, Factor Analysis

Authors

Author ORCID Identifier: N/A (Not provided in source material)

Affiliation Email addresses: N/A (Not provided in source material)

Correspondence Address: N/A (Not provided in source material)

Permissions & Fee and Test Year

The scale was first published in 1979. Use and licensing often depend on the specific version (e.g., standard vs. structured interview guides). Researchers should consult the copyright holders, usually the authors or the journal publisher, for current permissions and fees regarding commercial use.

Reference’s

• Montgomery. S.A.‚ Asberg. M. (1979). A New Depression Scale Designed to be Sensitive to Change. British Journal of Psychiatry 134 (4): 382-389.
• Williams‚ J. B. W.; Kobak‚ K. A. (2008). “Development and reliability of a structured interview guide for the Montgomery-Asberg Depression Rating Scale (SIGMA)”. The British Journal of Psychiatry 192 (1): 52–58.
• Galinowski A‚ Lehert P: Structural validity of MADRS during antidepressant treatment. IntClin Psychopharmacol 1995; 10:157–61.

Items of the Montgomery-Asberg Depression Rating Scale (MADRS)

IMPORTANT: The following scale items must be preserved in their original language and must not be changed in any way.